Menu
Search
|

Menu

Close
X

Veracyte Inc VCYT.OQ (NASDAQ Stock Exchange Global Market)

5.70 USD
+0.09 (+1.60%)
As of Feb 16
chart
Previous Close 5.61
Open 5.57
Volume 33,376
3m Avg Volume 49,671
Today’s High 5.70
Today’s Low 5.54
52 Week High 9.78
52 Week Low 5.25
Shares Outstanding (mil) 33.89
Market Capitalization (mil) 312.50
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
35
FY16
65
FY15
50
EPS (USD)
FY17
-0.458
FY16
-1.106
FY15
-1.301
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
4.36
5.77
Price to Book (MRQ)
vs sector
6.53
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
53.15
16.52
LT Debt to Equity (MRQ)
vs sector
53.15
12.22
Return on Investment (TTM)
vs sector
-36.37
14.43
Return on Equity (TTM)
vs sector
-62.64
16.13

EXECUTIVE LEADERSHIP

Bonnie Anderson
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: $500,000.00
Bonus: --
Christopher Hall
President, Chief Operating Officer, Since 2017
Salary: $395,000.00
Bonus: --
Keith Kennedy
Chief Financial Officer, Since 2016
Salary: $28,975.00
Bonus: --
Julie Brooks
General Counsel, Secretary, Since 2014
Salary: --
Bonus: --
John Hanna
Chief Commercial Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

6000 Shoreline Ct Ste 300
SOUTH SAN FRANCISCO   CA   94080-7606

Phone: +1650.2436300

Veracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.

SPONSORED STORIES